JP2004534031A - 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物 - Google Patents

心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物 Download PDF

Info

Publication number
JP2004534031A
JP2004534031A JP2002588995A JP2002588995A JP2004534031A JP 2004534031 A JP2004534031 A JP 2004534031A JP 2002588995 A JP2002588995 A JP 2002588995A JP 2002588995 A JP2002588995 A JP 2002588995A JP 2004534031 A JP2004534031 A JP 2004534031A
Authority
JP
Japan
Prior art keywords
carvedilol
hours
released
pharmaceutical composition
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002588995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534031A5 (cg-RX-API-DMAC7.html
Inventor
ディリプ、シャンティラル、シャングビ
バーラ、ラメシャ、アール．チャリー
ツィアウディン、ゼット．ティエブジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2004534031A publication Critical patent/JP2004534031A/ja
Publication of JP2004534031A5 publication Critical patent/JP2004534031A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Packaging Frangible Articles (AREA)
JP2002588995A 2001-05-17 2002-05-10 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物 Pending JP2004534031A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (cg-RX-API-DMAC7.html) 2001-05-17 2001-05-17
PCT/IN2002/000118 WO2002092078A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Publications (2)

Publication Number Publication Date
JP2004534031A true JP2004534031A (ja) 2004-11-11
JP2004534031A5 JP2004534031A5 (cg-RX-API-DMAC7.html) 2005-09-29

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002588995A Pending JP2004534031A (ja) 2001-05-17 2002-05-10 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物

Country Status (16)

Country Link
US (1) US20030035836A1 (cg-RX-API-DMAC7.html)
EP (1) EP1395258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004534031A (cg-RX-API-DMAC7.html)
KR (1) KR20040037026A (cg-RX-API-DMAC7.html)
CN (1) CN1525855A (cg-RX-API-DMAC7.html)
AU (1) AU2002314515B2 (cg-RX-API-DMAC7.html)
BE (1) BE1014328A7 (cg-RX-API-DMAC7.html)
BR (1) BR0210976A (cg-RX-API-DMAC7.html)
CA (1) CA2447005A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400607A3 (cg-RX-API-DMAC7.html)
IN (1) IN191028B (cg-RX-API-DMAC7.html)
MX (1) MXPA03010501A (cg-RX-API-DMAC7.html)
PL (1) PL370589A1 (cg-RX-API-DMAC7.html)
RU (1) RU2003133446A (cg-RX-API-DMAC7.html)
WO (1) WO2002092078A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200309724B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505970A (ja) * 2009-09-29 2013-02-21 ティーエスエイチ バイオファーム コーポレーション リミテッド 徐放性カルベジロール製剤
JPWO2011102506A1 (ja) * 2010-02-22 2013-06-17 第一三共株式会社 経口用徐放性固形製剤

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051208A1 (en) 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
DE60224293T2 (de) * 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2483054A1 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US7268156B2 (en) 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
AU2003283789A1 (en) * 2002-11-22 2004-06-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
CA2520312C (en) * 2003-03-26 2013-06-18 Egalet A/S Matrix compositions for controlled delivery of drug substances
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
WO2004093850A1 (en) * 2003-04-24 2004-11-04 Jagotec Ag Tablet with coloured core
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
AU2004279318C1 (en) * 2003-09-12 2020-06-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
EP1691789B1 (en) 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
JP5161075B2 (ja) * 2005-06-03 2013-03-13 エガレット エイ／エス 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
ES2400446T5 (es) 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
TW201141544A (en) 2010-02-22 2011-12-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
JP2003514019A (ja) * 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
EP1272180B1 (en) * 2000-04-03 2004-09-29 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
JP2004518734A (ja) * 2000-10-24 2004-06-24 スミスクライン・ビーチャム・コーポレイション カルベジロールの新規処方

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505970A (ja) * 2009-09-29 2013-02-21 ティーエスエイチ バイオファーム コーポレーション リミテッド 徐放性カルベジロール製剤
US8883207B2 (en) 2009-09-29 2014-11-11 Tsh Biopharm Corporation Ltd. Controlled release carvedilol formulation
JPWO2011102506A1 (ja) * 2010-02-22 2013-06-17 第一三共株式会社 経口用徐放性固形製剤

Also Published As

Publication number Publication date
AU2002314515B2 (en) 2007-08-16
RU2003133446A (ru) 2005-03-10
HUP0400607A2 (hu) 2004-07-28
MXPA03010501A (es) 2004-03-02
ZA200309724B (en) 2005-05-25
US20030035836A1 (en) 2003-02-20
KR20040037026A (ko) 2004-05-04
CA2447005A1 (en) 2002-11-21
HUP0400607A3 (en) 2005-07-28
CN1525855A (zh) 2004-09-01
BE1014328A7 (fr) 2003-08-05
BR0210976A (pt) 2004-10-05
PL370589A1 (en) 2005-05-30
WO2002092078A1 (en) 2002-11-21
EP1395258A1 (en) 2004-03-10
IN191028B (cg-RX-API-DMAC7.html) 2003-09-13

Similar Documents

Publication Publication Date Title
JP2004534031A (ja) 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物
AU2002314515A1 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
JP5420590B2 (ja) ｐＨ非依存延長放出性医薬組成物
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
US20120135079A1 (en) Modified Release Tranexamic Acid Formulation
US6150410A (en) pH independent extended release pharmaceutical formulation
US20030099710A1 (en) Granule modulating hydrogel system
EP1673073A1 (en) Sustained-release formulations
US20060147530A1 (en) Sustained release compositions containing alfuzosin
CN115297848B (zh) 一种非布司他片
EP2010158B1 (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
WO2003075830A2 (en) Oral controlled drug delivery system containing carbamazepine
WO2003011256A1 (en) Oral controlled release pharmaceutical composition of a prokinetic agent
WO2009024858A1 (en) Controlled release dosage form of galantamine
WO2003030920A9 (en) An antispasmodic agent spaced drug delivery system
JP4696210B2 (ja) イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法
US20150209292A1 (en) Controlled release formulations and preparation method thereof
US20040228918A1 (en) Granule modulating hydrogel system
US20040265381A1 (en) Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
MXPA01007814A (es) Formulacion farmaceutica de libekracion prolongada independiente al ph

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090327

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090612